Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.
All Keywords
【저자키워드】 SARS-CoV-2, autoimmune hemolytic anemia, COVID-19 mRNA vaccine, warm autoimmune hemolytic anemia, immune-mediated hemolysis, 【초록키워드】 COVID-19, coronavirus disease, Vaccine, complement, outcomes, Asymptomatic, Patient, red blood cell, autoantibody, Activation, second dose, heterogeneous, disorder, RBCs, form, receiving, characterized, suffered, 【제목키워드】 COVID-19, hemolytic, acid, messenger,
【저자키워드】 SARS-CoV-2, autoimmune hemolytic anemia, COVID-19 mRNA vaccine, warm autoimmune hemolytic anemia, immune-mediated hemolysis, 【초록키워드】 COVID-19, coronavirus disease, Vaccine, complement, outcomes, Asymptomatic, Patient, red blood cell, autoantibody, Activation, second dose, heterogeneous, disorder, RBCs, form, receiving, characterized, suffered, 【제목키워드】 COVID-19, hemolytic, acid, messenger,